Arrowhead Pharmaceuticals, Inc. (ARWR)
| Market Cap | 8.86B +73.6% |
| Revenue (ttm) | 669.50M +16.8% |
| Net Income | -319.96M |
| EPS | -2.28 |
| Shares Out | 141.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,764,864 |
| Open | 60.72 |
| Previous Close | 60.74 |
| Day's Range | 60.44 - 62.99 |
| 52-Week Range | 34.61 - 95.49 |
| Beta | 1.30 |
| Analysts | Strong Buy |
| Price Target | 107.23 (+70.88%) |
| Est. Earnings | Nov 24, 2026 |
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ... [Read more]
Financial Performance
In fiscal year 2025, Arrowhead Pharmaceuticals's revenue was $829.45 million, an increase of 23258.15% compared to the previous year's $3.55 million. Losses were -$1.63 million, -99.73% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for ARWR stock is "Strong Buy." The 12-month stock price target is $107.23, which is an increase of 70.88% from the latest price.
News
Arrowhead announces US FDA granted plozasiran entry into STAR program
Arrowhead (ARWR) Pharmaceuticals announced that the United States Food and Drug Administration, FDA, has granted plozasiran entry in the Split Real Time Application Review, STAR, pilot program in conn...
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in th...
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will fo...
Arrowhead resumed with a Neutral at Goldman Sachs
Goldman Sachs analyst Andrea Newkirk resumed coverage of Arrowhead (ARWR) with a Neutral rating and $74 price target Goldman resumed coverage of the biotechnology sector, saying the group has continue...
Arrowhead Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A broad RNAi platform is driving expansion into multiple indications, with REDEMPLO launched for FCS and a major SHTG launch targeted for 2027. Recent pivotal trials showed strong efficacy and safety, while new programs in obesity, CNS, and dimer technology signal continued pipeline growth.
Arrowhead Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The conference highlighted strong early clinical data for dual gene knockdown in mixed hyperlipidemia, a differentiated and rapidly advancing triglyceride-lowering therapy, and a robust pipeline targeting CNS and metabolic diseases. Commercial execution is progressing well, with a focus on innovation and leveraging AI for discovery.
Arrowhead announces interim topline data from Phase 1/2a trial of ARO-DIMER-PA
Arrowhead (ARWR) Pharmaceuticals announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference, RNAi, therapeutic dimer being de...
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's first investigati...
Arrowhead Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Recent clinical data for plozasiran in SHTG show strong efficacy and a differentiated safety profile, with positive physician feedback and a focus on high-risk patient segments. Launch preparations are advanced, pricing has been well received by payers, and the company is prioritizing full U.S. commercialization while keeping future pipeline options open.
Citi adds ‘upside 30-day catalyst watch’ on Arrowhead
Citi analyst Eric Joseph added an “upside 30-day catalyst watch” on Arrowhead (ARWR) while keeping a Buy rating on the shares with a $108 price target Citi believes the shares…
Arrowhead initiated with a Buy at Citi
Citi initiated coverage of Arrowhead (ARWR) with a Buy rating and $108 price target The firm sees Arrowhead as a “compelling multipronged play” in the cardiovascular space. Citi is bullish…
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: 2026 Cantor G...
Arrowhead Pharmaceuticals Transcript: KOL event
Plozasiran demonstrated robust, sustained triglyceride and acute pancreatitis risk reduction in SHTG, with a favorable safety profile and strong commercial potential. The initial launch will target high-risk patients, supported by advanced regulatory and market readiness.
Arrowhead Pharmaceuticals Press release: KOL event
Arrowhead Pharmaceuticals issued a press release on August 31, 2026, disclosing material business information to investors.
Arrowhead Pharmaceuticals Slides: KOL event
Arrowhead Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 31, 2026.
Arrowhead Phase 3 SHASTA-3, SHASTA-4 studies met primary endpoints
Arrowhead (ARWR) Pharmaceuticals presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with severe hypertriglyceridemia during a Hot Line Late-Breaking Scien...
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
PASADENA, Calif.--(BUSINESS WIRE)-- #arrowheadpharma--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adu...
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present important new data at the European Society of Cardiology Congress (ESC) in Munich...
Arrowhead announces availability of REDEMPLO for FCS in Germany
Arrowhead (ARWR) Pharmaceuticals announced that people in Germany who live with a rare metabolic condition called Familial Chylomicronaemia Syndrome are the among first in the European Union to have a...
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that people in Germany who live with a rare metabolic condition called Familial Chylomicronaemia Syndr...
Arrowhead price target raised to $120 from $115 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Arrowhead (ARWR) to $120 from $115 and keeps a Buy rating on the shares. The firm cites the one quarter pull-forward in…
Arrowhead price target raised to $104 from $98 at Stifel
Stifel raised the firm’s price target on Arrowhead (ARWR) to $104 from $98 and keeps a Buy rating on the shares.
Arrowhead Pharmaceuticals Earnings Call Transcript: Q3 2026
SHASTA-3/4 phase III trials showed strong efficacy and safety for plozasiran in SHTG, supporting a planned sNDA submission by year-end 2026. REDEMPLO prescriptions more than doubled, with expanding global approvals and a robust pipeline advancing. Cash reserves of $1.6B support ongoing launches and R&D.
Arrowhead Pharmaceuticals Quarterly report: Q3 2026
Arrowhead Pharmaceuticals has published its Q3 2026 quarterly earnings report on August 4, 2026.
Arrowhead Pharmaceuticals Earnings release: Q3 2026
Arrowhead Pharmaceuticals released its Q3 2026 earnings on August 4, 2026, summarizing the period's financial results.